Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy
2020 ◽
Vol 10
(4)
◽
pp. 204589402096096
◽
Keyword(s):
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis. Pulmonary arterial hypertension due to checkpoint inhibitor use has not yet been described. We present a novel case of pulmonary arterial hypertension associated with systemic lupus erythematosus and Sjogren’s syndrome overlap that was induced by therapy with the checkpoint inhibitor durvalumab.
2019 ◽
Vol 25
(8)
◽
pp. 1867-1872
◽
2021 ◽
Vol 147
(2)
◽
pp. AB11
2020 ◽
2021 ◽
Vol 39
(15_suppl)
◽
pp. e16194-e16194